Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 258 publications
Tumor emboli-associated adaptive stress response signatures identify aggressive disease features in inflammatory breast cancer.
Journal: bioRxiv : the preprint server for biology
Published: July 17, 2026
Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 11, 2026
Adverse Events in a Randomized Trial Comparing Radiotherapy with or without Olaparib for Inflammatory Breast Cancer.
Journal: International journal of radiation oncology, biology, physics
Published: April 13, 2026
Definitive, stereotactic ablative radiotherapy and endocrine therapy without surgery for select low-risk breast cancers: A prospective, phase II trial.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: March 14, 2026
Impact of Tamoxifen Only After Lumpectomy for "Good-Risk" Duct Carcinoma In Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials.
Journal: International journal of radiation oncology, biology, physics
Published: March 09, 2026
Serum S100A8/S100A9 is associated with increased risk of brain metastasis in patients with inflammatory breast cancer.
Journal: medRxiv : the preprint server for health sciences
Published: February 06, 2026
In Reply to Kunkler et al.
Journal: International journal of radiation oncology, biology, physics
Published: January 18, 2026
Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.
Journal: The Lancet. Oncology
Published: January 11, 2026
Cholesterol efflux protein, ABCA1, supports anticancer functions of myeloid immune cells.
Journal: Science advances
Published: January 01, 2026
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer.
Journal: ESMO open
Published: November 04, 2025
Last Updated: 09/26/2026